Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
Version v23-FR | Version v7-EN | |
---|---|---|
Language | French | English |
Date Updated | 2021-02-16 | 2019-03-22 |
Drug Identification Number | 02091887 | 02091887 |
Brand name | RIFADIN | RIFADIN |
Common or Proper name | Rifadin 150mg | Rifadin 150mg |
Company Name | SANOFI-AVENTIS CANADA INC | SANOFI-AVENTIS CANADA INC |
Ingredients | RIFAMPIN | RIFAMPIN |
Strength(s) | 150MG | 150MG |
Dosage form(s) | CAPSULE | CAPSULE |
Route of administration | ORAL | ORAL |
Packaging size | 100 | 100 |
ATC code | J04AB | J04AB |
ATC description | DRUGS FOR TREATMENT OF TUBERCULOSIS | DRUGS FOR TREATMENT OF TUBERCULOSIS |
Reason for shortage | Other (Please describe in comments) | Other (Please describe in comments) |
Anticipated start date | 2019-06-28 | 2019-06-28 |
Actual start date | 2019-07-03 | |
Estimated end date | Unknown | 2020-04-01 |
Actual end date | 2021-01-28 | |
Shortage status | Resolved | Anticipated shortage |
Tier 3 Status | No | No |
Company comments | July 15th, 2020: Rifadin strengths are in Dormant status The shortage is due to a production delay and an increase in demand. Sanofi is working diligently to make the product available as soon as possible. We are in communication with Health Canada to work towards reducing the duration of the backorder. Sanofi has no supply remaining at its warehouse or at the wholesale level. | We are working diligently to make the product available as soon as possible. We are in communication with Health Canada to work towards reducing the duration of the backorder. To optimize the distribution of the product ans its availability for patients, order quantities will be limited per purchase order. |
Health Canada comments |